BRIP1 and hepatocellular carcinoma: The dose of 50 nmol/L was selected for all other three cell types, showing 80% reduction of BRIP1 in CAMA‐1 and MDA‐MB‐231 (Figure 2B‐C), respectively, and 70% inhibition in HCC‐1500 (Figure 2D).